The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib
Abstract Recently Food and Drug Administration (FDA)-approved pralsetinib (BLU-667) and selpercatinib (LOXO-292) are RET-selective protein tyrosine kinase inhibitors for treating RET-altered cancers, but whether they have distinct activity was unknown. The L730V/I mutations at the roof of the solven...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Portfolio
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/a56a59cbb9894e42849b0e49e6d4e170 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|